Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H3RAKLES: Tucatinib and trastuzumab in HER3-mutant, HER2-non-amplified metastatic breast cancer
2024-519624-24-00Phase 2Authorised
- Sponsor
- Institut Curie
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucatinib and trastuzumab in breast cancer, sponsored by Institut Curie. Primary endpoint: Clinical benefit rate (CBR). Planned start Sep 2025; status: authorised.
02
Drugs
tucatinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-519624-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519624-24-00.